Literature DB >> 9634495

Evaluating tumor biology and oncological disease with positron-emission tomography.

D H Silverman1, C K Hoh, M A Seltzer, C Schiepers, G S Cuan, S S Gambhir, L Zheng, J Czernin, M E Phelps.   

Abstract

The usefulness of positron-emission tomography (PET) for noninvasive assessment of several biological parameters of neoplastic tissue has been reviewed. Numerous radiotracers have been developed, whose particular distribution in the presence of cancer in vivo serves to distinguish medically relevant properties of the tumor cells with which they associate. That distribution is most accurately determined through use of a PET scanner, to localize and quantify the tracer molecules, in which have been incorporated positron-emitting isotopes. These tracers include hypoxia markers, receptor ligands, substrates for enzymatic modification by the products of expression of specific genes, and precursors of protein anabolism and carbohydrate catabolism. In addition, application of PET to evaluation of patients with some particular cancers has been examined, while placing special emphasis on the level of scientific rigor of the evidence underlying conclusions about appropriate use of PET in oncology. Copyright 1998 W.B. Saunders Company.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9634495     DOI: 10.1016/s1053-4296(98)80044-1

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  6 in total

1.  Evaluation of [¹²³I]-CLINDE as a potent SPECT radiotracer to assess the degree of astroglia activation in cuprizone-induced neuroinflammation.

Authors:  Filomena Mattner; David Linares Bandin; Maria Staykova; Paula Berghofer; Marie Claude Gregoire; Patrice Ballantyne; Mitchell Quinlivan; Susan Fordham; Tien Pham; David O Willenborg; Andrew Katsifis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

2.  How morphometric analysis of metastatic load predicts the (un)usefulness of PET scanning: the case of lymph node staging in melanoma.

Authors:  G S Mijnhout; O S Hoekstra; A van Lingen; P J van Diest; H J Adèr; A A Lammertsma; R Pijpers; S Meijer; G J J Teule
Journal:  J Clin Pathol       Date:  2003-04       Impact factor: 3.411

3.  Positron emission tomography with computed tomography imaging of neuroinflammation in experimental autoimmune encephalomyelitis.

Authors:  Caius G Radu; Chengyi J Shu; Stephanie M Shelly; Michael E Phelps; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-29       Impact factor: 11.205

Review 4.  Novel imaging approaches to head and neck cancer.

Authors:  Kenneth A Krohn; Bevan Yeuh
Journal:  Semin Oncol       Date:  2008-06       Impact factor: 4.929

5.  Evaluation of the therapeutic efficacy of a MEK inhibitor (TAK-733) using ¹⁸F-fluorodeoxyglucose-positron emission tomography in the human lung xenograft model A549.

Authors:  Seigo Ishino; Hiroshi Miyake; Patrick Vincent; Ikuo Mori
Journal:  Ann Nucl Med       Date:  2015-05-27       Impact factor: 2.668

6.  Based on biomedical index data: Risk prediction model for prostate cancer.

Authors:  Hanxu Guo; Xianjie Jia; Hao Liu
Journal:  Medicine (Baltimore)       Date:  2021-04-30       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.